Assessment of the clinical benefit of cancer drugs receiving accelerated approval B Gyawali, SP Hey, AS Kesselheim JAMA Internal Medicine 179 (7), 906-913, 2019 | 246 | 2019 |
A systematic review of trial-level meta-analyses measuring the strength of association between surrogate end-points and overall survival in oncology A Haslam, SP Hey, J Gill, V Prasad European Journal of Cancer 106, 196-211, 2019 | 173 | 2019 |
Are outcome-adaptive allocation trials ethical? SP Hey, J Kimmelman Clinical Trials 12 (2), 102-106, 2015 | 118 | 2015 |
The questionable use of unequal allocation in confirmatory trials SP Hey, J Kimmelman Neurology 82 (1), 77-79, 2014 | 115 | 2014 |
Evaluating the evidence behind the surrogate measures included in the FDA's table of surrogate endpoints as supporting approval of cancer drugs B Gyawali, SP Hey, AS Kesselheim EClinicalMedicine 21, 2020 | 111 | 2020 |
Assessment of the role of niacin in managing cardiovascular disease outcomes: a systematic review and meta-analysis E D’Andrea, SP Hey, CL Ramirez, AS Kesselheim JAMA network open 2 (4), e192224-e192224, 2019 | 80 | 2019 |
Benefit, risk, and outcomes in drug development: a systematic review of sunitinib B Carlisle, N Demko, G Freeman, A Hakala, N MacKinnon, T Ramsay, ... Journal of the National Cancer Institute 108 (1), djv292, 2016 | 72 | 2016 |
A comparison of response patterns for progression-free survival and overall survival following treatment for cancer with PD-1 inhibitors: a meta-analysis of correlation and … B Gyawali, SP Hey, AS Kesselheim JAMA Network Open 1 (2), e180416-e180416, 2018 | 67 | 2018 |
Is the concept of clinical equipoise still relevant to research? SP Hey, AJ London, C Weijer, A Rid, F Miller BMJ 359, 2017 | 44 | 2017 |
Countering imprecision in precision medicine SP Hey, AS Kesselheim Science 353 (6298), 448-449, 2016 | 41 | 2016 |
The ethical challenges raised in the design and conduct of pragmatic trials: an interview study with key stakeholders SG Nicholls, K Carroll, M Zwarenstein, JC Brehaut, C Weijer, SP Hey, ... Trials 20, 1-16, 2019 | 38 | 2019 |
Heuristics and Meta-heuristics in Scientific Judgement SP Hey The British Journal for the Philosophy of Science 67 (2), 471-495, 2014 | 37 | 2014 |
Cell and gene therapy trials: are we facing an ‘evidence crisis’? M Abou-El-Enein, SP Hey EClinicalMedicine 7, 13-14, 2019 | 36 | 2019 |
A Systematic Review Of The Food And Drug Administration’s ‘Exception From Informed Consent’ Pathway WB Feldman, SP Hey, AS Kesselheim Health Affairs 37 (10), 1605-1614, 2018 | 34 | 2018 |
Heterogeneity of antidiabetic treatment effect on the risk of major adverse cardiovascular events in type 2 diabetes: a systematic review and meta-analysis E D’Andrea, AS Kesselheim, JM Franklin, EH Jung, SP Hey, E Patorno Cardiovascular Diabetology 19, 1-11, 2020 | 31 | 2020 |
Cluster over individual randomization: are study design choices appropriately justified? Review of a random sample of trials M Taljaard, CE Goldstein, B Giraudeau, SG Nicholls, K Carroll, SP Hey, ... Clinical Trials 17 (3), 253-263, 2020 | 31 | 2020 |
A framework for assessing scientific merit in ethical review of clinical research A Binik, SP Hey Ethics & human research 41 (2), 2-13, 2019 | 27 | 2019 |
A review of pragmatic trials found a high degree of diversity in design and scope, deficiencies in reporting and trial registry data, and poor indexing SG Nicholls, K Carroll, SP Hey, M Zwarenstein, JZ Zhang, HP Nix, ... Journal of clinical epidemiology 137, 45-57, 2021 | 26 | 2021 |
Public approval of exception from informed consent in emergency clinical trials: a systematic review of community consultation surveys WB Feldman, SP Hey, JM Franklin, AS Kesselheim JAMA Network Open 2 (7), e197591-e197591, 2019 | 26 | 2019 |
Developing a framework for the ethical design and conduct of pragmatic trials in healthcare: a mixed methods research protocol M Taljaard, C Weijer, JM Grimshaw, A Ali, JC Brehaut, MK Campbell, ... Trials 19, 1-13, 2018 | 26 | 2018 |